Health
Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease
CAMBRIDGE, Mass., January 07, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the submission of its clinical trial application (CTA) for Study SRP-1005-101, also known as INSIGHTT, to Medsafe, the New Zealand Medicines and Medical Devices Safety Authority. Pending approval, Sarepta expects to initiate this first-in-human clinical trial of SRP-1005 (formerly ARO-HTT) in the second quarter of 2026. SRP-1005 is an investiga
About this update from Sarepta Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":426,"url":"https://media.zenfs.com/en/business-wire.com/b5253695c40ba2feeeb4bf29798f6cb3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GOZ88UStaRawqtXtaf0TMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTg1MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b5253695c40ba2feeeb4bf29798f6cb3","width":480,"height":426}},"lazy":false},{"type":"text","content":"– The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026","length":118,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., January 07, 2026--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the submission of its clinical trial application (CTA) for Study SRP-1005-101, also known as INSIGHTT, to Medsafe, the New Zealand Medicines and Medical Devices Safety Authority. Pending approval, Sarepta expects to initiate this first-in-human clinical trial of SRP-1005 (formerly ARO-HTT) in the second quarter of 2026. SRP-1005 is an investigational small interfering RNA (siRNA) therapeutic for the treatment of Huntington’s Disease.","length":608,"tagName":"p"},{"type":"text","content":""Huntington’s disease is a devastating, progressive condition with extremely limited therapeutic options and no approved treatments to slow or halt its course. Families carry the burden across generations, and the need for new approaches is urgent," said Louise Rodino-Klapac, Ph.D., president of research & development and technical operations, Sarepta. "SRP-1005, a subcutaneously dosed siRNA therapy intended to target the deep brain and knock down the protein that causes Huntington’s disease, represents a novel and potentially paradigm changing approach to the treatment of this devastating disease."","length":630,"tagName":"p"},{"type":"text","content":"INSIGHTT is a Phase 1, multi-center, dose escalation study that will evaluate the safety and tolerability of subcutaneous dosing of SRP-1005 in approximately 24 participants. SRP-1005 leverages an advanced TfR1 (transferrin receptor protein 1) approach that uses monovalent fragment antigen binding (fAb) designed for efficient delivery to ...